{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:54:46Z","timestamp":1794588886354,"version":"4.9.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.xcrm.2021.100346","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T13:05:00Z","timestamp":1626872700000},"page":"100346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine"],"prefix":"10.1016","volume":"2","author":[{"given":"Helena","family":"Chaytow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiterie M.E.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Gillingwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2021.100346_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2021.100346_bib3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib5","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.xcrm.2021.100346_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib7","doi-asserted-by":"crossref","first-page":"a075","DOI":"10.1093\/braincomms\/fcaa075","article-title":"Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy","volume":"2","author":"Wadman","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.xcrm.2021.100346_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/scitranslmed.aay9648","article-title":"Efficacy and costs of spinal muscular atrophy drugs","volume":"12","author":"Darrow","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib143","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib144","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 \u2013 A prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2021.100346_bib145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41587-020-0706-x","article-title":"First oral SMA drug","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2021.100346_bib146","series-title":"Media & Investor Release","year":"2021"},{"key":"10.1016\/j.xcrm.2021.100346_bib147","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.nmd.2017.06.411","article-title":"Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results","volume":"2017","author":"Charnas","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.xcrm.2021.100346_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib11","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2021.100346_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2021.100346_bib13","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib15","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","article-title":"Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models","volume":"23","author":"Osman","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib16","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2021.100346_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib18","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2021.100346_bib19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.xcrm.2021.100346_bib22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.xcrm.2021.100346_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib24","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100346_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2021.100346_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib27","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2021.100346_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2021.100346_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nmd.2018.10.001","article-title":"The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy","volume":"29","author":"Kletzl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib35","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.xcrm.2021.100346_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2021.100346_bib37","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.xcrm.2021.100346_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100346_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"Sergott","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.xcrm.2021.100346_bib42","series-title":"Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington\u2019s disease (HD)","year":"2020"},{"key":"10.1016\/j.xcrm.2021.100346_bib43","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/MCB.01301-09","article-title":"Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing","volume":"30","author":"Younis","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.xcrm.2021.100346_bib44","doi-asserted-by":"crossref","first-page":"17472","DOI":"10.1038\/s41598-020-74346-9","article-title":"Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy","volume":"10","author":"Ando","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib45","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s41598-018-20219-1","article-title":"Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy","volume":"8","author":"Sapaly","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib46","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/mt.2016.145","article-title":"Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy","volume":"24","author":"Osman","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib47","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2021.100346_bib48","first-page":"1","article-title":"Clinical Experience with Gene Therapy in Older Spinal Muscular Atrophy Patients","volume":"2021","author":"Matesanz","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-019-00606-6","article-title":"Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis","volume":"33","author":"Elshafay","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.xcrm.2021.100346_bib148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.27091","article-title":"Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis","volume":"63","author":"Paganoni","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2021.100346_bib149","doi-asserted-by":"crossref","first-page":"20585","DOI":"10.1038\/s41598-020-77197-6","article-title":"Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study","volume":"10","author":"Kawamura","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib150","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.xcrm.2021.100346_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.xcrm.2021.100346_bib75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib152","article-title":"Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study","author":"Rudnicki","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.xcrm.2021.100346_bib153","series-title":"Cochrane Database of Systematic Reviews","article-title":"Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis\/motor neuron disease","author":"Mitchell","year":"2007"},{"key":"10.1016\/j.xcrm.2021.100346_bib94","doi-asserted-by":"crossref","first-page":"e019932","DOI":"10.1136\/bmjopen-2017-019932","article-title":"Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)","volume":"8","author":"Stam","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.xcrm.2021.100346_bib98","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","article-title":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","volume":"29","author":"Frongia","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib154","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nmd.2018.07.013","article-title":"Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy?","volume":"28","author":"Pera","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan","year":"2009","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.xcrm.2021.100346_bib49","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in\u00a0vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib52","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1016\/j.bmcl.2017.06.027","article-title":"Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells","volume":"27","author":"Lai","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.xcrm.2021.100346_bib53","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","article-title":"Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice","volume":"86","author":"Tsai","year":"2008","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.xcrm.2021.100346_bib55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.21449","article-title":"Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition","volume":"64","author":"Narver","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1747-0285.2009.00781.x","article-title":"Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy","volume":"73","author":"Dayanga\u00e7-Erden","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.xcrm.2021.100346_bib59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jnc.14935","article-title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells","volume":"153","author":"Pagliarini","year":"2020","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.xcrm.2021.100346_bib61","doi-asserted-by":"crossref","first-page":"E2347","DOI":"10.1073\/pnas.1613181114","article-title":"SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage","volume":"114","author":"Jangi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2021.100346_bib62","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1093\/nar\/gky641","article-title":"Combined deficiency of Senataxin and DNA-PKcs causes DNA damage accumulation and neurodegeneration in spinal muscular atrophy","volume":"46","author":"Kannan","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2021.100346_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/brain\/awz373","article-title":"ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy","volume":"143","author":"Kannan","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.xcrm.2021.100346_bib64","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.chembiol.2004.08.024","article-title":"Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism","volume":"11","author":"Lunn","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.xcrm.2021.100346_bib65","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41598-018-38208-9","article-title":"Intraperitoneal delivery of a novel drug-like compound improves disease severity in severe and intermediate mouse models of Spinal Muscular Atrophy","volume":"9","author":"Osman","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib66","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00439-006-0245-7","article-title":"Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts","volume":"120","author":"Mattis","year":"2006","journal-title":"Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2012.07.024","article-title":"Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy","volume":"525","author":"Mattis","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.xcrm.2021.100346_bib68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3233\/JND-170230","article-title":"Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy","volume":"4","author":"Osman","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","article-title":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","volume":"88","author":"Foran","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib70","doi-asserted-by":"crossref","first-page":"e1006744","DOI":"10.1371\/journal.pgen.1006744","article-title":"Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy","volume":"13","author":"Boyd","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.xcrm.2021.100346_bib72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bcp.2019.07.002","article-title":"Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate","volume":"168","author":"Weber","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100346_bib74","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejphar.2017.08.005","article-title":"Edaravone is a candidate agent for spinal muscular atrophy: In\u00a0vitro analysis using a human induced pluripotent stem cells-derived disease model","volume":"814","author":"Ando","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100346_bib78","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11064-019-02814-4","article-title":"The Protective Effects of Levetiracetam on a Human iPSCs-Derived Spinal Muscular Atrophy Model","volume":"44","author":"Ando","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.xcrm.2021.100346_bib79","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI131989","article-title":"Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models","volume":"130","author":"Kim","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100346_bib80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12542","article-title":"Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy","volume":"11","author":"Zhou","year":"2020","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.xcrm.2021.100346_bib81","doi-asserted-by":"crossref","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","article-title":"Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xcrm.2021.100346_bib82","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/hmg\/ddn426","article-title":"Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy","volume":"18","author":"Rose","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2021.100346_bib85","series-title":"Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy","year":"2000"},{"key":"10.1016\/j.xcrm.2021.100346_bib86","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1113\/JP278235","article-title":"Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction","volume":"597","author":"Cheng","year":"2019","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.xcrm.2021.100346_bib87","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2014.84","article-title":"Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice","volume":"22","author":"Tsai","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib88","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41434-020-0146-8","article-title":"Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice","volume":"27","author":"Ahlskog","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib90","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/hmg\/ddx124","article-title":"Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in model mice","volume":"26","author":"Kim","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2020.07.031","article-title":"AAV9-DOK7 gene therapy reduces disease severity in Smn2B\/- SMA model mice","volume":"530","author":"Kaifer","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2021.100346_bib92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fncel.2018.00017","article-title":"Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy","volume":"12","author":"Boido","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.xcrm.2021.100346_bib93","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2021.100346_bib95","doi-asserted-by":"crossref","unstructured":"Stam, M., Wijngaarde, C.A., Bartels, B., Asselman, F.-L., Otto, L.A.M., Goedee, S., et al. (2019). Space trial. A phase II, monocenter, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2, 3 and 4. In Proceedings of the 23rd Cure SMA Researcher Meeting. 74.","DOI":"10.1136\/bmjopen-2017-019932"},{"key":"10.1016\/j.xcrm.2021.100346_bib96","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JND-170293","article-title":"Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders","volume":"5","author":"Clausen","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2021.100346_bib99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","article-title":"Effect of Salbutamol on Respiratory Muscle Strength in Spinal Muscular Atrophy","volume":"73","author":"Khirani","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2012.09.011","article-title":"SMN is required for sensory-motor circuit function in Drosophila","volume":"151","author":"Imlach","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2021.100346_bib101","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2020.07.007","article-title":"Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients","volume":"30","author":"Chiriboga","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2021.100346_bib102","first-page":"4703","article-title":"Synaptotagmin-2, and -1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy","volume":"25","author":"Tejero","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib103","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.isci.2020.100826","article-title":"R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy","volume":"23","author":"Tejero","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2021.100346_bib104","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/hmg\/ddr425","article-title":"The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin","volume":"20","author":"N\u00f6lle","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib105","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib106","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"10","author":"Bowerman","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.xcrm.2021.100346_bib107","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mt.2014.209","article-title":"PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy","volume":"23","author":"Little","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib108","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/hmg\/ddq058","article-title":"Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy","volume":"19","author":"Wen","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2021.100346_bib112","doi-asserted-by":"crossref","first-page":"e0132364","DOI":"10.1371\/journal.pone.0132364","article-title":"Plastin 3 expression does not modify spinal muscular atrophy severity in the \u03947 SMA mouse","volume":"10","author":"McGovern","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xcrm.2021.100346_bib113","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajhg.2019.05.008","article-title":"NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice","volume":"105","author":"Torres-Benito","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib114","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1093\/brain\/awy167","article-title":"CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis","volume":"141","author":"Janzen","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.xcrm.2021.100346_bib115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12915-020-00845-w","article-title":"Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy","volume":"18","author":"Walsh","year":"2020","journal-title":"BMC Biol."},{"key":"10.1016\/j.xcrm.2021.100346_bib116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.mcn.2014.06.006","article-title":"Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy","volume":"61","author":"Custer","year":"2014","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.xcrm.2021.100346_bib117","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41419-017-0086-4","article-title":"Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy","volume":"8","author":"Piras","year":"2017","journal-title":"Cell Death Dis."},{"issue":"Pt A","key":"10.1016\/j.xcrm.2021.100346_bib118","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2016.06.032","article-title":"Autophagy modulators regulate survival motor neuron protein stability in motoneurons","volume":"283","author":"Periyakaruppiah","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.xcrm.2021.100346_bib119","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1007\/s12035-018-1379-z","article-title":"Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice","volume":"56","author":"de la Fuente","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.xcrm.2021.100346_bib120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ajhg.2007.09.009","article-title":"Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy","volume":"82","author":"Ramser","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib121","doi-asserted-by":"crossref","first-page":"e87908","DOI":"10.1172\/jci.insight.87908","article-title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy","volume":"1","author":"Powis","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2021.100346_bib122","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Disrupted ubiquitin homeostasis and beta-catenin signalling in spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100346_bib123","doi-asserted-by":"crossref","first-page":"e88427","DOI":"10.1172\/jci.insight.88427","article-title":"ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice","volume":"1","author":"Abera","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2021.100346_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells9102190","article-title":"JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases","volume":"9","author":"Musi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2021.100346_bib125","first-page":"6986","article-title":"Genetic inhibition of JNK3 ameliorates spinal muscular atrophy","volume":"24","author":"Genabai","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib126","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/hmg\/ddz150","article-title":"Motor neuron loss in SMA is not associated with somal stress-activated JNK\/c-Jun signaling","volume":"28","author":"Pilato","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib127","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fnmol.2018.00308","article-title":"Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice","volume":"11","author":"Schellino","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.xcrm.2021.100346_bib128","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1016\/j.celrep.2019.11.058","article-title":"Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy","volume":"29","author":"Simon","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib129","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1016\/j.celrep.2017.12.003","article-title":"Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Article Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy","volume":"21","author":"Simon","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib130","doi-asserted-by":"crossref","first-page":"130574","DOI":"10.1172\/jci.insight.130574","article-title":"Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons","volume":"5","author":"Osman","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2021.100346_bib131","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/hmg\/ddt191","article-title":"Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation","volume":"22","author":"Farooq","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib132","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/hmg\/ddt477","article-title":"Chondrolectin affects cell survival and neuronal outgrowth in in\u00a0vitro and in\u00a0vivo models of spinal muscular atrophy","volume":"23","author":"Sleigh","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib133","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.celrep.2019.09.033","article-title":"Interaction of Axonal Chondrolectin with Collagen XIXa1 Is Necessary for Precise Neuromuscular Junction Formation","volume":"29","author":"Opri\u015foreanu","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2021.100346_bib134","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/1381612822666151124235028","article-title":"Neuroprotective Mechanisms Mediated by CDK5 Inhibition","volume":"22","author":"Mushtaq","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.xcrm.2021.100346_bib135","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1523\/JNEUROSCI.3716-14.2015","article-title":"Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy","volume":"35","author":"Miller","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.xcrm.2021.100346_bib136","doi-asserted-by":"crossref","first-page":"e0128560","DOI":"10.1371\/journal.pone.0128560","article-title":"Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model","volume":"10","author":"Valsecchi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xcrm.2021.100346_bib137","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ymthe.2020.01.013","article-title":"miR-206 Reduces the Severity of Motor Neuron Degeneration in the Facial Nuclei of the Brainstem in a Mouse Model of SMA","volume":"28","author":"Valsecchi","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2021.100346_bib138","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1093\/hmg\/ddz142","article-title":"AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B\/-SMA model mice","volume":"28","author":"Kaifer","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2021.100346_bib139","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.3390\/ijms22115913","article-title":"Metabolic Dysfunction in Spinal Muscular Atrophy","volume":"22","author":"Deguise","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2021.100346_bib140","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fphys.2019.01258","article-title":"Low-Intensity Running and High-Intensity Swimming Exercises Differentially Improve Energy Metabolism in Mice With Mild Spinal Muscular Atrophy","volume":"10","author":"Houdebine","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.xcrm.2021.100346_bib141","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.xcrm.2021.100346_bib142","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1093\/hmg\/ddaa146","article-title":"Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy","volume":"29","author":"Motyl","year":"2020","journal-title":"Hum. Mol. Genet."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121001956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121001956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:48:38Z","timestamp":1762987718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379121001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":154,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2666379121001956"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100346","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100346"}}